Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway

noticia |

Hamnvik O.-P.R., Choueiri T.K., Turchin A., McKay R.R., Goyal L., Davis M., Kaymakcalan M.D., Williams J.S.

Cancer 2015 121:2 (311-319)

BACKGROUND: VEGF signaling pathway inhibitor (anti-VEGF) therapy is associated with hypertension, but little is known about predisposing clinical characteristics. This study describes the real-world association between baseline clinical characteristics, blood pressure (BP) response, and survival in patients prescribed anti-VEGF therapies. METHODS: Clinical data from Partners HealthCare in Massachusetts was obtained from adults treated with anti-VEGF therapies (2002-2013). Treatment-induced hypertensive response was defined as worsening of preexisting hypertension or new diagnosis of hypertension (if no prior hypertension history). RESULTS: Data from 1120 patients with renal cell carcinoma (32.2%), hepatocellular carcinoma (11.6%), gastrointestinal stromal tumors (12.5%), and other sarcomas (15.3%) were analyzed. Most patients received sunitinib (52%), sorafenib (25.9%), or pazopanib (18%)…(vermás)


1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)